SPY749.60−0.63%QQQ674.25−0.83%BTC/USD67,185.49−1.53%DIA521.21−0.37%GLD355.70+0.07%TLT79.42+0.05%

uniQure NV

QURENASDAQ

Trade with Public

$23.81

-0.82-3.33%

At close: Nov 13, 4:00 PM EST

$23.81

N/A

After Hours: 4:00 PM EST

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

uniQure (QURE) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for uniQure (QURE) stock.

Analyst Consensus — 12 Analysts

9Buy

3Hold

# Analysts12

Latest Upgrades and Downgrades for uniQure Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	UBS	Joon Lee	Assumes	Buy	$27→$48
—	Barclays	Eliana Merle	Downgrade	Overweight→Equal-Weight	$60→$28
—	RBC Capital	Luca Issi	PT Cut	Outperform	$65→$48
—	Goldman Sachs	Salveen Richter	PT Cut	Neutral	$46→$31
—	William Blair	Sami Corwin	Reinstates	Outperform	—
—	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$60→$75
—	Wolfe Research	Rudy Li	Upgrade	Peer Perform→Outperform	$65
—	Barclays	Eliana Merle	PT Cut	Overweight	$65→$60
—	HC Wainwright & Co.	Patrick R. Trucchio	PT Raise	Buy	$50→$80
—	Mizuho	Uy Ear	PT Raise	Outperform	$35→$68
—	Barclays	Eliana Merle	Upgrade	Equal-Weight→Overweight	$25→$65
—	Goldman Sachs	Salveen Richter	PT Raise	Neutral	$14→$46
—	Leerink Partners	Joseph Schwartz	PT Raise	Outperform	$36→$70
—	RBC Capital	Luca Issi	PT Raise	Outperform	$35→$65
—	HC Wainwright & Co.	Patrick R. Trucchio	PT Cut	Buy	$70→$50
—	Chardan Capital	Daniil Gataulin	PT Raise	Buy	$31→$37
—	Goldman Sachs	Salveen Richter	PT Raise	Neutral	$9→$10
—	Barclays	Eliana Merle	PT Cut	Equal-Weight	$31→$25
—	Mizuho	Uy Ear	Upgrade	Neutral→Outperform	$12→$35
—	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$70

uniQure NV

uniQure (QURE) Stock Price Target 2026

Latest Upgrades and Downgrades for uniQure Stock

uniQure (QURE) Stock Price Target 2026

Latest Upgrades and Downgrades for uniQure Stock

Analyst Ratings News

FDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals

PRO
Barclays Downgrades uniQure to Equal-Weight, Lowers Price Target to $28

PRO
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $48

PRO
Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31

PRO
William Blair Reinstates Outperform on uniQure

PRO
Wells Fargo Maintains Overweight on uniQure, Raises Price Target to $75

People Also Watch

People Also Watch

Analyst Ratings News

FDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals

PRO
Barclays Downgrades uniQure to Equal-Weight, Lowers Price Target to $28

PRO
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $48

PRO
Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31

PRO
William Blair Reinstates Outperform on uniQure

PRO
Wells Fargo Maintains Overweight on uniQure, Raises Price Target to $75

uniQure NV

uniQure (QURE) Stock Price Target 2026

Latest Upgrades and Downgrades for uniQure Stock

uniQure (QURE) Stock Price Target 2026

Latest Upgrades and Downgrades for uniQure Stock

Analyst Ratings News

FDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals

PROBarclays Downgrades uniQure to Equal-Weight, Lowers Price Target to $28

PRORBC Capital Maintains Outperform on uniQure, Lowers Price Target to $48

PROGoldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31

PROWilliam Blair Reinstates Outperform on uniQure

PROWells Fargo Maintains Overweight on uniQure, Raises Price Target to $75

People Also Watch

People Also Watch

Analyst Ratings News

FDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals

PROBarclays Downgrades uniQure to Equal-Weight, Lowers Price Target to $28

PRORBC Capital Maintains Outperform on uniQure, Lowers Price Target to $48

PROGoldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31

PROWilliam Blair Reinstates Outperform on uniQure

PROWells Fargo Maintains Overweight on uniQure, Raises Price Target to $75

PRO
Barclays Downgrades uniQure to Equal-Weight, Lowers Price Target to $28

PRO
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $48

PRO
Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31

PRO
William Blair Reinstates Outperform on uniQure

PRO
Wells Fargo Maintains Overweight on uniQure, Raises Price Target to $75

PRO
Barclays Downgrades uniQure to Equal-Weight, Lowers Price Target to $28

PRO
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $48

PRO
Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31

PRO
William Blair Reinstates Outperform on uniQure

PRO
Wells Fargo Maintains Overweight on uniQure, Raises Price Target to $75